Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19370310 | 1.00 | HTR2A (0.41) | HTR2AHTR2CHTR2BPDE4BLTA4H | |
| SCHEMBL19370311 | 1.00 | HTR2A (0.41) | HTR2AHTR2CHTR2BPDE4BLTA4H | |
| SCHEMBL15185051 | 0.82 | PDE4B (0.37) | PDE4BPDE4DNOTUM | |
| SCHEMBL19708769 | 0.81 | HTR2A (0.39) | HTR2AHTR2CHTR2BEIF2AK4 | |
| SCHEMBL20940079 | 0.78 | LTA4H (0.40) | PDE4BLTA4HDPP4LRRK2PDE4D | |
| SCHEMBL23138573 | 0.77 | LTA4H (0.34) | PDE4BLTA4HDPP4EIF2AK4NOTUM | |
| SCHEMBL18590395 | 0.77 | LTA4H (0.36) | PDE4BLTA4HDPP4EIF2AK4NOTUM | |
| SCHEMBL18590394 | 0.77 | LTA4H (0.36) | PDE4BLTA4HDPP4EIF2AK4NOTUM | |
| SCHEMBL16853906 | 0.77 | LTA4H (0.34) | PDE4BLTA4HDPP4EIF2AK4NOTUM | |
| SCHEMBL15451877 | 0.77 | LTA4H (0.41) | PDE4BLTA4HDPP4EIF2AK4LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223759-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Broadenbio Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023114157-A2 | PYRAZOLOPYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | MERCK SHARP & DOHME LLC (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023034812-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. | 2023-02-16 | — | — | US | disclosed |
| WO-2022261243-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022095904-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京伯汇生物技术有限公司 | 2022-05-12 | — | — | WO | disclosed |
| WO-2020247298-A2 | 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020112872-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2019113175-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| EP-3083615-B1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2019-04-17 | — | — | EP | disclosed |
| WO-2015104356-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-07-16 | — | — | WO | disclosed |
| US-20150197529-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150175597-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20140343059-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2014-11-20 | — | — | US | disclosed |
| US-8822472-B2 | Piperazines, pharmaceutical compositions and methods of use thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140031330-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH INC (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2014009447-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | disclosed |
| US-20120071652-A1 | Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-7943622-B2 | Piperazines, pharmaceutical compositions and methods of use thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343059-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA2 | HTR2A 174/4885HTR2C 184/4885HTR2B 201/4885 |
| US-20150197529-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | HTR2A 787/4885HTR2C 615/4885HTR2B 1015/4885 |
| US-20120071652-A1 | Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof | CHRNA7, CHRNA5, CHRNA2 | HTR2A 174/4885HTR2C 184/4885HTR2B 201/4885 |
| US-20150175597-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | DAPK1, BAD, FASTKD1 | HTR2A 4830/4885HTR2C 4863/4885HTR2B 4849/4885 |
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | NSD1, NSD3, EHMT1 | HTR2A 4335/4885HTR2C 4192/4885HTR2B 4403/4885 |
| US-20140031330-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | HTR2A 801/4885HTR2C 609/4885HTR2B 1026/4885 |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | CHRNA7, CHRNA5, CHRNA2 | HTR2A 174/4885HTR2C 184/4885HTR2B 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.